Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.

OBJECTIVE The recurrence rate of anti-SSA/Ro-associated congenital heart block (CHB) is 17%. Sustained reversal of third-degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB. METHODS A multicenter, prospective, open-label study based on Simon's 2-stage optimal design was initiated. Enrollment criteria included the presence of anti-SSA/Ro antibodies in the mother, birth of a previous child with CHB/neonatal lupus rash, current treatment with < or = 20 mg/day of prednisone, and <12 weeks pregnant. IVIG (400 mg/kg) was given every 3 weeks from week 12 to week 24 of gestation. The primary outcome was the development of second-degree or third-degree CHB. RESULTS Twenty mothers completed the IVIG protocol before the predetermined stopping rule of 3 cases of advanced CHB in the study was reached. CHB was detected at 19, 20, and 25 weeks; none of the cases occurred following the finding of an abnormal PR interval on fetal Doppler monitoring. One of these mothers had 2 previous children with CHB. One child without CHB developed a transient rash consistent with neonatal lupus. Sixteen children had no manifestations of neonatal lupus at birth. No significant changes in maternal titers of antibody to SSA/Ro, SSB/La, or Ro 52 kd were detected over the course of therapy or at delivery. There were no safety issues. CONCLUSION This study establishes the safety of IVIG and the feasibility of recruiting pregnant women who have previously had a child with CHB. However, IVIG at low doses consistent with replacement does not prevent the recurrence of CHB or reduce maternal antibody titers.

[1]  J. Buyon,et al.  Anti-SSA/Ro and Anti-SSB/La Autoantibodies Bind the Surface of Apoptotic Fetal Cardiocytes and Promote Secretion of TNF-α by Macrophages1 , 2000, The Journal of Immunology.

[2]  Mimi Y. Kim,et al.  Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block: The PR Interval and Dexamethasone Evaluation (PRIDE) Prospective Study , 2008, Circulation.

[3]  R. Hynes,et al.  A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. , 2006, Blood.

[4]  J. Buyon,et al.  Antibody Reactivity to α-Enolase in Mothers of Children with Congenital Heart Block , 2009, The Journal of Rheumatology.

[5]  D. Friedman,et al.  Pulsed Doppler echocardiographic assessment of the fetal PR interval. , 2000, The American journal of cardiology.

[6]  J. Ravetch,et al.  Identification of a receptor required for the anti-inflammatory activity of IVIG , 2008, Proceedings of the National Academy of Sciences.

[7]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[8]  V. Lennon,et al.  Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. , 1999, The New England journal of medicine.

[9]  A. Tincani,et al.  Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. , 2001, Arthritis and rheumatism.

[10]  H. Julkunen,et al.  The rate of recurrence of isolated congenital heart block: a population-based study. , 2001, Arthritis and rheumatism.

[11]  D. Roopenian,et al.  Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. , 2005, The Journal of clinical investigation.

[12]  D. Friedman,et al.  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside , 2009, Nature Clinical Practice Rheumatology.

[13]  J. Huggins,et al.  Use of intravenous immunoglobulin G (IVIG). , 2006, Best practice & research. Clinical haematology.

[14]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[15]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[16]  J. Buyon,et al.  Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. , 2006, The Journal of clinical investigation.

[17]  Mimi Y. Kim,et al.  Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. , 2009, Arthritis and rheumatism.

[18]  R. Berkowitz,et al.  Antepartum Treatment Without Early Cordocentesis for Standard-Risk Alloimmune Thrombocytopenia: A Randomized Controlled Trial , 2007, Obstetrics and gynecology.

[19]  A Tincani,et al.  Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. , 2010, Arthritis and rheumatism.

[20]  J. Ravetch,et al.  Anti-inflammatory actions of intravenous immunoglobulin. , 2008, Annual review of immunology.

[21]  N. Silverman,et al.  Maternal Anti-Ro and Anti-La Antibody–Associated Endocardial Fibroelastosis , 2002, Circulation.

[22]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[23]  R. Hansen,et al.  Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor , 2002, Thrombosis and Haemostasis.

[24]  Mimi Y. Kim,et al.  Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. , 2009, The American journal of cardiology.

[25]  J. Buyon.  Autoimmune-Associated Congenital Heart Block , 1999 .

[26]  J. Buyon,et al.  Autoantibody-Associated Congenital Heart Block: Outcome in Mothers and Children , 1994, Annals of Internal Medicine.

[27]  R. Kaaja,et al.  Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. , 2003, Arthritis and rheumatism.

[28]  J. Buyon,et al.  Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. , 2004, Arthritis and rheumatism.

[29]  J. Buyon,et al.  Transdifferentiation of Cardiac Fibroblasts, a Fetal Factor in Anti-SSA/Ro-SSB/La Antibody-Mediated Congenital Heart Block1 , 2002, The Journal of Immunology.

[30]  R. Friedman,et al.  Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. , 2001, Journal of the American College of Cardiology.

[31]  A. Ahmed,et al.  Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  J. M. Osborne,et al.  Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. , 1996, Journal of immunology.

[33]  Y. El‐Sayed,et al.  A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. , 2000, American journal of obstetrics and gynecology.

[34]  D. Friedman,et al.  Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. , 1998, Journal of the American College of Cardiology.

[35]  J. Buyon,et al.  Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. , 2004, Arthritis and rheumatism.